Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Company Overview - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases [2] - The company's lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist aimed at treating metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) [2] Upcoming Events - Members of Altimmune's management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 2:30 p.m. ET [1] - The session will be available via webcast on the Altimmune website [1]